AOD-9604 vs Retatrutide: HGH Fragment vs Triple Agonist in Weight Research
Last Updated: April 27, 2026
See also: Our Complete Guide to Retatrutide Research Peptide covers full clinical trial data, mechanism of action, safety profile, and sourcing considerations.
In the landscape of metabolic research peptides, few comparisons illustrate the diversity of mechanism as clearly as AOD-9604 versus retatrutide. One is a fragment of human growth hormone that works directly on fat cells. The other is a cutting-edge triple receptor agonist that simultaneously engages three separate receptor pathways. Understanding their differences is essential for researchers selecting compounds for fat metabolism studies, designing combination protocols, or interpreting published preclinical data.
For a complete overview of this research area, see the GLP-1 Peptide Research Guide 2026 from Palmetto Peptides.
For a full overview of GLP-1 class peptides including retatrutide, see our GLP-1 Peptide Research Guide 2026. For a comparison of AOD-9604 with semaglutide specifically, see AOD-9604 vs Semaglutide: Comparing Fat Metabolism Research Approaches.
Last Updated: April 27, 2026 | Reading Time: Approximately 9 minutes | Author: Palmetto Peptides Research Team
Quick Answer
AOD-9604, a fragment of human growth hormone targeting fat metabolism, and retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, take very different mechanistic approaches to weight-related research -- AOD-9604 works through a single, narrower pathway while retatrutide's triple-agonism produces broader effects in preclinical models.